SDC1 and acute lymphoblastic leukemia: Indeed, enhanced expression of Serglycin, Syndecan-1/CD138, Perlecan, Endocan, Fibromodulin Podocalyxin and Versican may be used in association with other biomarkers to further stratify children with ALL in lower and higher risk patients for receiving standard-of-care therapeutic treatments [104, 106, 122–125].